# A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

> **NCT05991388** · PHASE2,PHASE3 · RECRUITING · sponsor: **University of Birmingham** · enrollment: 210 (estimated)

## Conditions studied

- B-cell Non Hodgkin Lymphoma

## Interventions

- **DRUG:** Odronextamab
- **DRUG:** Loncastuximab tesirine
- **DRUG:** Rituximab
- **DRUG:** Ifosfamide
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Etoposide Phosphate
- **DRUG:** Dexamethasone
- **BIOLOGICAL:** CAR T-cells (TBC)

## Key facts

- **NCT ID:** NCT05991388
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-02
- **Primary completion:** 2031-05-01
- **Final completion:** 2033-05-01
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05991388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05991388, "A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05991388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*